ac HBRP Publication Page 28-38 2023. All Rights Reserved Page 28 Journal of Advances in Drug Discovery and Development Volume 1 Issue 1 Development and Validation of HPTLC Method for Simultaneous Estimation of Azelnidipine and Telmisartan Heta Kachhiya 1 *, Jinal Tandel 2 1,2 Assistant Professor, Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipcowala College of Pharmacy, A constituent college of the Charutar Vidya Mandal University, New V. V. Nagar, Anand, Gujarat, India Isha Rupchandani 3 , Adit Velani 4 , Suchi Patel 5 , Krupa Patel 6 , Nirali Zala 7 3,4,5,6,7 Student, Department of Pharmaceutical Chemistry and Analysis, Indukaka Ipcowala College of Pharmacy, A constituent college of the Charutar Vidya Mandal University, New V. V. Nagar, Anand, Gujarat, India *Corresponding Author E-Mail Id: hetaben.kachhiya@cvmu.edu.in ABSTRACT HPTLC method for simultaneous estimation of Azelnidipine and Telmisartan in bulk and their pharmaceutical dosage form was developed and validated. Pre coated silica gel G60-F 254 aluminium sheet as a stationary phase and Toluene: Acetonitrile: Formic acid (5:4.5:0.5 % V/V/V) as mobile phase was optimized to develop chromatograph. The method shown linearity in the range of 200-700 ng/ band for Azelnidipine and 1000-3500 ng/band for Telmisartan with R 2 0.9961 and 0.9971 for Azelnidipine and Telmisartan respectively. %Recovery of 100.1 to 103.8% for Azelnidipine and 99.59 to 100.8% for Telmisartan was achieved by applying standard spiking method of accuracy study. LOD and LOQ values were 24.71 ng/band and 74.90 ng/bank for Azelnidipine. LOD and LOQ values were 175.04 ng/band and 530.44 ng/bank for Telmisartan. A sensitive, accurate, precise, rapid, cost effective and less time-consuming method is repeatable and selective for the analysis of Azelnidipine and Telmisartan without having any interference from excipients. Keywords: Azelnidipine, telmisartan, high performance thin layer chromatography, validation Article Highlights Quantification of Azelnidipine and Telmisartan in combined dosage form by Planar Chromatography INTRODUCTION Azelnidipine[1] (AZL) inhibits trans- membrane Ca+2 influxes through vascular smooth muscle voltage-dependent channels. L-type, T-type, N-type, P/Q- type, and R-type Ca+2 channels are among the different types of Ca+2 channels. Ca+2 channels of the L type. Calcium normally causes smooth muscle contraction, which contributes to hypertension. The vascular smooth muscle does not contract when calcium channels are closed, resulting in vascular smooth muscle wall relaxation and lower blood pressure. Azelnidipine is 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4- dihydropyridine-3,5-dicarboxylate with molecular formula C33H34N4O6 and 582.6 gm/mole of molecular weight. Telmisartan2 (TEL) is an angiotensin II receptor antagonist used to treat hypertension. It has been connected to a modest rate of transitory serum amino- transferase increases but not to cases of